You are on page 1of 5

Angiotensin-Converting Enzyme

Inhibitor-Induced Cough
ACCP Evidence-Based Clinical Practice Guidelines
Peter V. Dicpinigaitis, MD, FCCP
Background: A dry, persistent cough is a well-described class effect of the angiotensin-converting
enzyme (ACE) inhibitor medications. The mechanism of ACE inhibitor-induced cough remains
unresolved, but likely involves the protussive mediators bradykinin and substance P, agents that
are degraded by ACE and therefore accumulate in the upper respiratory tract or lung when the
enzyme is inhibited, and prostaglandins, the production of which may be stimulated by
bradykinin.
Methods: Data for this review were obtained from a National Library of Medicine (PubMed)
search, which was performed in May 2004, of the literature published in the English language
from 1985 to 2004, using the search terms angiotensin-converting enzyme, angiotensin
converting enzyme inhibitors, and cough.
Results: The incidence of ACE inhibitor-induced cough has been reported to be in the range
of 5 to 35% among patients treated with these agents. However, a much lower incidence has
been described in studies of patients presenting for the evaluation of chronic cough. The
onset of ACE inhibitor-induced cough ranges from within hours of the first dose to months
after the initiation of therapy. Resolution typically occurs within 1 to 4 weeks after the
cessation of therapy, but cough may linger for up to 3 months. The only uniformly effective
treatment for ACE inhibitor-induced cough is the cessation of treatment with the offending
agent. The incidence of cough associated with therapy with angiotensin-receptor blockers
appears to be similar to that of the control drug. In a minority of patients, cough will not recur
after the reintroduction of ACE inhibitor therapy.
Conclusions: In a patient with chronic cough, ACE inhibitors should be considered as wholly
or partially causative, regardless of the temporal relation between the initiation of ACE
inhibitor therapy and the onset of cough. Although the cessation of therapy is the only
uniformly effective treatment for ACE inhibitor-induced cough, some pharmacologic agents
have been shown to attenuate the cough. (CHEST 2006; 129:169S173S)
Key words: angiotensin-converting enzyme; angiotensin-converting enzyme inhibitors; angiotensin receptor
blockers; bradykinin; capsaicin; cough; prostaglandins; substance P
Abbreviations: ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker
C
hronic cough is a well-described class effect of
the angiotensin-converting enzyme (ACE) in-
hibitors.
1
The cough is typically dry and is associ-
ated with a tickling or scratching sensation in the
throat. The incidence of ACE inhibitor-induced
cough has been reported
1,2
to be in the range of 5
to 35% among patients who have been treated
with these agents. However, in prospective, de-
scriptive studies
35
that evaluated the etiology of
chronic cough in patients presenting for evaluation
of this symptom, ACE inhibitors were determined
to be responsible in 0 to 3% of cases. ACE
inhibitor-induced cough is not dose-dependent.
1
Patients treated with ACE inhibitors for conges-
Reproduction of this article is prohibited without written permission
from the American College of Chest Physicians (www.chestjournal.
org/misc/reprints.shtml).
Correspondence to: Peter Dicpinigaitis, MD, FCCP, Einstein
Division/Montefiore Medical Center, 1825 Eastchester Rd, Bronx,
NY 10461; e-mail: pdicpinigaitis@pol.net
www.chestjournal.org CHEST / 129 / 1 / JANUARY, 2006 SUPPLEMENT 169S
Downloaded From: http://journal.publications.chestnet.org/ on 10/21/2013
tive heart failure cough more frequently than
those treated with these agents for hypertension.
2
Cough due to ACE inhibitors occurs more com-
monly in women,
69
nonsmokers,
1,8
and persons of
Chinese origin.
10,11
Cough may occur within hours of the first dose of
medication, or its onset can be delayed for weeks to
months after the initiation of therapy. Treatment
with ACE inhibitors may sensitize the cough reflex,
thereby potentiating other causes of chronic cough.
12
Although cough usually resolves within 1 to 4 weeks
of the cessation of therapy with the offending drug,
in a subgroup of individuals cough may linger for up
to 3 months.
1,13
Although the etiology of ACE inhibitor-induced
cough remains an unresolved issue, new develop-
ments since the publication of the first American
College of Chest Physician consensus panel report
include studies implicating the bradykinin receptor
as relevant to ACE inhibitor function as well as the
cough associated with these medications. Several
new therapeutic agents have been added to the list of
drugs that may attenuate ACE inhibitor-induced
cough in some patients. Furthermore, an accumulat-
ing body of evidence supports the concept that the
angiotensin receptor blockers (ARBs) do not cause
cough, including in those patients with a history of
ACE inhibitor-induced cough. Data for this review
were obtained from a National Library of Medicine
(PubMed) search, which was performed in May
2004, of the literature published in the English
language from 1985 to 2004, using the search terms
angiotensin-converting enzyme, angiotensin-con-
verting enzyme inhibitors, and cough.
Recommendation
1. In patients presenting with chronic cough,
in order to determine that the ACE inhibitor is
the cause of the cough, therapy with ACE
inhibitors should be discontinued regardless of
the temporal relation between the onset of
cough and the initiation of ACE inhibitor ther-
apy. The diagnosis is confirmed by the resolu-
tion of cough, usually within 1 to 4 weeks of the
cessation of the offending agent; however, the
resolution of cough may be delayed in a sub-
group of patients for up to 3 months. Quality of
evidence, low; net benefit, substantial; grade of
recommendation, B
Pathogenesis
The mechanism of ACE inhibitor-induced cough
remains unclear. Possible protussive mediators in-
clude bradykinin and substance P, which are de-
graded by ACE and therefore accumulate in the
upper airway or lung when the enzyme is inhibited;
and prostaglandins, the production of which may be
stimulated by bradykinin.
1,14
Bradykinin-induced
sensitization of airway sensory nerves has been pro-
posed as a potential mechanism of ACE inhibitor-
induced cough.
14
Some evidence has suggested that
the therapeutic effect of ACE inhibitors may involve
the activation of bradykinin receptors,
15
and that
bradykinin receptor gene polymorphism is associated
with the cough that is related to ACE inhibitors.
16
The enhancement of bronchial responsiveness does
not appear to be a relevant mechanism.
17
Subjects
with ACE inhibitor-induced cough demonstrate in-
creased cough reflex sensitivity to experimental stim-
ulation with capsaicin,
12
which resolves after the
discontinuation of therapy with the inciting drug.
18
Treatment
The only uniformly effective intervention for ACE
inhibitor-induced cough is the cessation of therapy
with the offending agent. Numerous small studies
have evaluated various drugs as potential therapies
(Table 1). Agents demonstrating the ability to atten-
uate cough due to ACE inhibitors in randomized,
double-blind, placebo-controlled trials include in-
haled sodium cromoglycate,
19
theophylline,
20
sulin-
dac,
21
indomethacin,
22
the calcium-channel antago-
nists amlodipine and nifedipine,
22
ferrous sulfate,
23
and the thromboxane receptor antagonist picotamide
(not available in the United States).
24
In open-label,
uncontrolled studies, agents shown to suppress ACE
inhibitor-induced cough include the -aminobutyric
acid agonist baclofen,
25
the thromboxane synthetase
inhibitor ozagrel,
26
and aspirin, 500 mg/d (low-dose
therapy with aspirin was found to be ineffective).
27
One randomized, double-blind, parallel-group,
controlled trial
13
demonstrated that about 30% of
patients with ACE inhibitor-induced cough who had
been challenged and dechallenged twice did not
develop cough after a third trial of ACE inhibitor
therapy.
13
Therefore, in patients whose cough re-
solves after the cessation of ACE inhibition therapy
and for whom there is a compelling reason to treat
with these agents, a repeat trial of ACE inhibitor
therapy may be attempted.
Recommendations
2. In patients presenting with chronic ACE
inhibitor-induced cough, discontinue therapy
170S Diagnosis and Management of Cough: ACCP Guidelines
Downloaded From: http://journal.publications.chestnet.org/ on 10/21/2013
with the drug because it is the only uniformly
effective treatment. Quality of evidence, low; net
benefit, substantial; grade of recommendation, B
3. In patients whose cough resolves after the
cessation of therapy with ACE inhibitors, and
for whom there is a compelling reason to treat
with these agents, a repeat trial of ACE inhibi-
tor therapy may be attempted. Quality of evi-
dence, fair; net benefit, substantial; grade of recom-
mendation, A
4. In patients for whom the cessation of ACE
inhibitor therapy is not an option, pharmaco-
logic therapy, including that with sodium cro-
moglycate, theophylline, sulindac, indometha-
cin, amlodipine, nifedipine, ferrous sulfate, and
picotamide that is aimed at suppressing cough
should be attempted. Quality of evidence, fair; net
benefit, intermediate; grade of recommendation, B
Theoretically, the recently introduced ARBs
should not induce cough, because their mechanism
of action does not involve the inhibition of ACE with
the resultant elevation of tissue levels of bradykinin
and substance P. Indeed, losartan, the first ARB that
was approved for clinical use, has been associated
with a low incidence of cough, similar to that of the
diuretic hydrochlorothiazide, in patients with a his-
tory of ACE inhibitor-induced cough.
13
Numerous
comparative trials
28,29
have subsequently been per-
formed, demonstrating the lower incidence of cough
associated with several ARBs compared to that with
ACE inhibitors.
Recommendation
5. In patients in whom persistent or intoler-
able ACE inhibitor-induced cough occurs, ther-
apy should be switched, when indicated, to an
ARB, with which the incidence of associated
cough appears to be similar to that for the
control drug, or to an appropriate agent of
another drug class. Quality of evidence, good; net
benefit, substantial; grade of recommendation, A
Summary of Recommendations
1. In patients presenting with chronic
cough, in order to determine that the ACE
inhibitor is the cause of the cough, therapy
with ACE inhibitors should be discontinued
regardless of the temporal relation between
Table 1Drugs Shown to Attenuate Cough Due to ACE Inhibitors
Treatment Study
Patients,
No.
Age,*
yr Dosing Results p Value
Sodium cromoglycate Hargreaves and
Benson
19
10 4977 10 mg inhaled qid, for 14 d Reduction in 9/10 patients 0.01
Theophylline Cazolla et al
20
10 3374 8.5 mg/kg po qd, for 14 d Remission in 8/10 patients
Sulindac McEwan et al
21
6 4666 200 mg po qd, 7 d 37% reduction in cough
score
Indomethacin Fogari et al
22
33 4265 50 mg po bid, 14 d Eliminated in 27%,
significantly reduced in
69% of patients
0.01
Amlodipine Fogari et al
22
33 4265 5 mg po qd, 14 d Eliminated in 6%,
significantly reduced in
61% of patients
0.05
Nifedipine Fogari et al
22
33 4265 30 mg po qd, 14 d Eliminated in 3%,
significantly reduced in
51% of patients
0.05
Ferrous sulfate Lee et al
23
19 59.9 12.2 256 mg po qd, 28 d 45% reduction in mean
cough score
0.01
Picotamide Malini et al
24
9 3969 600 mg po bid, 14 d Significant
reduction/elimination in
8/9 patients
0.001
Baclofen Dicpinigaitis
25
7 4373 510 mg po tid, 28 d 64% reduction in mean
cough score
Ozagrel Umemura et al
26
10 60 11 200 mg po qd, 3060 d Reduced or eliminated in
8/10 patients
0.012
Aspirin Tenenbaum et al
27
14 63 11 500 mg po qd, 7 d Reduced or eliminated in
8/9 patients
0.002
*Values are given as mean SD or range.
www.chestjournal.org CHEST / 129 / 1 / JANUARY, 2006 SUPPLEMENT 171S
Downloaded From: http://journal.publications.chestnet.org/ on 10/21/2013
the onset of cough and the initiation of ACE
inhibitor therapy. The diagnosis is con-
firmed by the resolution of cough, usually
within 1 to 4 weeks of the cessation of the
offending agent; however, the resolution of
cough may be delayed in a subgroup of
patients for up to 3 months. Quality of evi-
dence, low; net benefit, substantial; grade of
recommendation, B
2. In patients presenting with chronic
ACE inhibitor-induced cough, discontinue
therapy with the drug because it is the only
uniformly effective treatment. Quality of ev-
idence, low; net benefit, substantial; grade of
recommendation, B
3. In patients whose cough resolves af-
ter the cessation of therapy with ACE
inhibitors, and for whom there is a com-
pelling reason to treat with these agents, a
repeat trial of ACE inhibitor therapy may
be attempted. Quality of evidence, fair; net
benefit, substantial; grade of recommendation,
A
4. In patients for whom the cessation of
ACE inhibitor therapy is not an option,
pharmacologic therapy, including that
with sodium cromoglycate, theophylline,
sulindac, indomethacin, amlodipine, ni-
fedipine, ferrous sulfate, and picotamide
that is aimed at suppressing cough should
be attempted. Quality of evidence, fair; net
benefit, intermediate; grade of recommenda-
tion, B
5. In patients in whom persistent or intol-
erable ACE inhibitor-induced cough occurs,
therapy should be switched, when indi-
cated, to an ARB, with which the incidence
of associated cough appears to be similar to
that for the control drug, or to an appropri-
ate agent of another drug class. Quality of
evidence, good; net benefit, substantial; grade of
recommendation, A
References
1 Israili ZH, Hall WD. Cough and angioneurotic edema asso-
ciated with angiotensin-converting enzyme inhibitor therapy:
a review of the literature and pathophysiology. Ann Intern
Med 1992; 117:234242
2 Ravid D, Lishner M, Lang R, et al. Angiotensin-converting
enzyme inhibitors and cough: a prospective evaluation in
hypertension and in congestive heart failure. J Clin Pharma-
col 1994; 34:11161120
3 Mello CJ, Irwin RS, Curley FJ. The predictive values of the
character, timing, and complications of chronic cough in
diagnosing its cause. Arch Intern Med 1996; 156:9971003
4 Irwin RS, Curley FJ, French CL. Chronic cough: the spec-
trum and frequency of causes, key components of the diag-
nostic evaluation, and outline of specific therapy. Am Rev
Respir Dis 1990; 141:640647
5 Smyrnios NA, Irwin RS, Curley FJ. Chronic cough with a
history of excessive sputum production: the spectrum and
frequency of causes and key components of the diagnostic
evaluation, and outcome of specific therapy. Chest 1995;
108:991997
6 Os I, Bratland B, Dahlof B, et al. Female preponderance for
lisinopril-induced cough in hypertension. Am J Hypertens
1994; 7:10121015
7 Coulter DM, Edwards IR. Cough associated with captopril
and enalapril. BMJ 1987; 294:15211523
8 Strocchi E, Malini PL, Valtancoli G, et al. Cough during
treatment with angiotensin converting enzyme inhibitors:
analysis of predisposing factors. Drug Invest 1992; 4:6972
9 Gibson GR. Enalapril-induced cough. Arch Intern Med 1989;
149:27012703
10 Woo J, Chan TYK. A high incidence of cough associated with
combination therapy of hypertension with isradipine and
lisinopril in Chinese subjects. Br J Clin Pract 1991; 45:178
180
11 Woo KS, Nicholls MG. High prevalence of persistent cough
with angiotensin converting enzyme inhibitors in Chinese.
Br J Clin Pharmacol 1995; 40:141144
12 Morice AH, Lowry R, Brown MJ, et al. Angiotensin-
converting enzyme and the cough reflex. Lancet 1987;
2:11161118
13 Lacourciere Y, Brunner H, Irwin RS, et al. Effects of
modulators of the renin-angiotensin-aldosterone system on
cough. J Hypertens 1994; 12:13871393
14 Fox AJ, Lalloo UG, Belvisi MG, et al. Bradykinin-evoked
sensitization of airway sensory nerves: a mechanism for
ACE-inhibitor cough. Nat Med 1996; 2:814817
15 Ignjatovic T, Tan F, Brovkovych V, et al. Novel mode of
action of angiotensin I converting enzyme inhibitors. J Biol
Chem 2002; 277:1684716852
16 Mukae S, Aoki S, Itoh S, et al. Bradykinin B
2
receptor gene
polymorphism is associated with angiotensin-converting en-
zyme inhibitor-related cough. Hypertension 2000; 36:127
131
17 Dicpinigaitis PV, Dobkin JB. Effect of angiotensin-converting
enzyme inhibition on bronchial responsiveness. J Clin Phar-
macol 1996; 36:361364
18 OConnell F, Thomas VE, Pride NB, et al. Capsaicin cough
sensitivity decreases with successful treatment of chronic
cough. Am J Respir Crit Care Med 1994; 150:374380
19 Hargreaves MR, Benson MK. Inhaled sodium cromoglycate
in angiotensin-converting enzyme inhibitor cough. Lancet
1995; 345:1316
20 Cazolla M, Matera MG, Liccardi G, et al. Theophylline in the
inhibition of angiotensin-converting enzyme inhibitor-in-
duced cough. Respiration 1993; 60:212215
21 McEwan JR, Choudry NB, Fuller RW. The effect of sulindac
on the abnormal cough reflex associated with dry cough.
J Pharmacol Exp Ther 1990; 255:161164
22 Fogari R, Zoppi A, Mugellini A, et al. Effects of amlodipine,
nifedipine GITS, and indomethacin on angiotensin-convert-
ing enzyme inhibitor-induced cough: a randomized, placebo-
controlled, double-masked, crossover study. Curr Ther Res
1999; 60:121128
23 Lee S-C, Park SW, Kim D-K, et al. Iron supplementation
inhibits cough associated with ACE inhibitors. Hypertension
2001; 38:166170
172S Diagnosis and Management of Cough: ACCP Guidelines
Downloaded From: http://journal.publications.chestnet.org/ on 10/21/2013
24 Malini PL, Strocchi E, Zanardi M, et al. Thromboxane
antagonism and cough induced by angiotensin-converting-
enzyme inhibitor. Lancet 1997; 350:1518
25 Dicpinigaitis PV. Use of baclofen to suppress cough induced
by angiotensin-converting enzyme inhibitors. Ann Pharmaco-
ther 1996; 30:12421245
26 Umemura K, Nakashima M, Saruta T. Thromboxane A
2
synthetase inhibitor suppresses cough induced by angio-
tensin converting enzyme inhibitors. Life Sci 1997; 60:
15831588
27 Tenenbaum A, Grossman E, Shemesh J, et al. Intermediate
but not low doses of aspirin can suppress angiotensin-
converting enzyme inhibitor-induced cough. Am J Hypertens
2000; 13:776782
28 Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-
induced cough and angioedema. Ann Pharmacother 1998;
32:10601066
29 Hernandez-Hernandez R, Sosa-Canache B, Velasco M, et al.
Angiotensin II receptor antagonists role in arterial hyperten-
sion. J Hum Hypertens 2002; 16(suppl):S93S99
www.chestjournal.org CHEST / 129 / 1 / JANUARY, 2006 SUPPLEMENT 173S
Downloaded From: http://journal.publications.chestnet.org/ on 10/21/2013

You might also like